/Infectious Disease Advisor requires free registration if more than 5 articles are viewed per month/
Switching to bictegravir plus emtricitabine and tenofovir alafenamide (BIC/FTC/TAF) represents a safe and effective regimen-optimization strategy among individuals with HIV who are virologically suppressed on antiretroviral therapy, according to study findings published in Infectious Diseases and Therapy.
Real-world data support long-acting antiretroviral therapy (ART) for people with HIV, including among those who are viremic at initiation, according to study findings published in Clinical Infectious Diseases.
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.